ALLMedicine™ Von Hippel-Lindau Disease Center

Apr 26th, 2022 - Familial neoplastic syndromes commonly impact the central and peripheral nervous systems. The most common neoplastic syndromes clinically relevant to neurology and neurologic surgery, include neurofibromatosis type 1, neurofibromatosis type 2, and...

Mar 25th, 2022 - Around 95% of patients with clinical features diagnostic of Von Hippel-Lindau disease (VHL) have a detectable inactivating germline variant in VHL. The VHL protein (pVHL) functions as part of the VCB-CR complex which plays a key role in oxygen sen...

Mar 10th, 2022 - Multiple sclerosis (MS) is a progressive autoimmune demyelinating disorder. Recent studies suggest that a combination of genetic susceptibility and environmental insult contributes to its pathogenesis. Many candidate genes have been discovered to ...

Feb 21st, 2022 - Von Hippel-Lindau (VHL) disease is an inherited tumour predisposition syndrome and a paradigm for the importance of early diagnosis and surveillance. However, there is limited information on the "real world" management of VHL disease. A national a...

Feb 9th, 2022 - Belzutifan: a novel therapy for von Hippel-Lindau disease.|2022|Zhou J,Gong K,|

Nov 1st, 2021 - Objective: Von Hippel-Lindau (VHL) disease is an autosomal dominant heritable disorder in which multiple benign and malignant neoplasms and cysts of specific histopathologies develop in the kidney, adrenal gland, pancreas, brain, spinal cord, eye,...

Apr 13th, 2021 - This open-label Phase 2 study will evaluate the efficacy, safety, PK, and PD of PT2385 in patients with VHL disease who have at least 1 measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). PT2385 will be administered orally an...

Nov 14th, 2018 - Background: Patients with the familial cancer syndrome von Hippel-Lindau (VHL) demonstrate manifestations in a variety of organs among them the pancreas. Pancreatic manifestations can range from benign cysts and micro cystic adenomas to neuroendoc...

Mar 4th, 2008 - The von Hippel Lindau (VHL) gene has recently been identified as the genetic defect resulting in a syndrome of multiple neoplasias. Patients with VHL disease develop retinal angiomata, renal cysts and/or carcinomas, CNS hemangioblastomas as well a...

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Dec 1st, 2021 - A novel oral agent may represent a game-changer for patients with von Hippel-Lindau (VHL) disease, a rare genetic disorder that increases the risk of renal cell carcinoma and other cancers, a new phase 2 trial suggests. The majority of patients wi...

Oct 20th, 2021 - Heloisa P. Soares, MD, PhD, medical oncologist, assistant professor, Huntsman Cancer Institute, University of Utah, discusses advances in the management of pancreatic neuroendocrine tumors (NETs). In January 2018, the FDA approved Lutetium 177 ...

Sep 14th, 2021 - Matthew H. Kulke, MD: Neuroendocrine tumors are actually a very broad category of malignancies. We tend to classify them broadly in 2 big groups. One group would be pancreatic neuroendocrine tumors and the other group would be extra-pancreatic neu...

Aug 13th, 2021 - The US Food and Drug Administration (FDA) approved belzutifan (Welireg) for adult patients with von Hippel-Lindau disease (VHL) who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancr...